Why the study?
Do first-generation and second-generation drug-eluting stents improve safety and efficacy compared to bare metal stents in patients with acute coronary syndromes?
Do first-generation and second-generation drug-eluting stents improve safety and efficacy compared to bare metal stents in patients with acute coronary syndromes?
This review highlights that drug-eluting stents have similar stent thrombosis rates to bare metal stents in acute coronary syndromes, supporting their safety and efficacy in this setting.
Answers are grounded in this paper and cite their sources.
May support drug-eluting stent safety in acute coronary syndromes; leaves open randomized confirmation before practice change.
Drug-eluting stents (DESs) are known to reduce in-stent restenosis rate, compared with bare metal stents (BMSs). Stent thrombosis, one of the most dangerous complications of DES, has emerged as a major concern. This issue has limited the use of DES in unstable coronary artery disease till recent years. In fact, acute coronary syndrome (ACS) and the subsequent activation of the hemocoagulative pathway could represent a prothrombotic environment, thus limiting the use of DES in this situation. Nowadays, there is increasing evidence in literature of similar stent thrombosis rates both for BMS and DES in ACS, and most interventional cardiologists are confident with the use of DES in ACS. The aim of this article is to review the current literature on this topic in order to compare first-generation and second-generation DES vs. BMS as concerns safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Gorla et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: